Tetrandrine as a Therapeutic Agent for COVID-19
P. M. Heister 1, †, University of Cambridge
R. N. Poston 2, †, Queen Mary University of London
1 ph535@cam.ac.uk
2 r.poston@qmul.ac.uk
† The authors contributed equally to this work
Running Head: Tetrandrine for COVID-19
Key words: coronavirus, SARS-CoV-2, two-pore channel 2 (TPC2),
endolysosomal pathway, calcium channel blocker, drug repurposing,
pharmacodynamics, pharmacokinetics, clinical trial, traditional Chinese
medicine.
Word count: 1861
Figure count: 1